CLDN22 Serves as a Novel Prognostic Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis.

Zheng H, Cheng J, Liu J, Liu G, Dang R, Luo R, Lou J

Open source

DOI
10.1155/ijog/9367254
Published
2025
Container
International journal of genomics
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1155/ijog/9367254,
  title = {CLDN22 Serves as a Novel Prognostic Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis.},
  author = {Zheng H and Cheng J and Liu J and Liu G and Dang R and Luo R and Lou J},
  year = {2025},
  journal = {International journal of genomics},
  doi = {10.1155/ijog/9367254},
  url = {https://doi.org/10.1155/ijog/9367254}
}

RIS

TY  - JOUR
TI  - CLDN22 Serves as a Novel Prognostic Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis.
AU  - Zheng H
AU  - Cheng J
AU  - Liu J
AU  - Liu G
AU  - Dang R
AU  - Luo R
AU  - Lou J
PY  - 2025
JO  - International journal of genomics
DO  - 10.1155/ijog/9367254
UR  - https://doi.org/10.1155/ijog/9367254
ER  - 

APA

H, Z., J, C., J, L., G, L., R, D., R, L., & J, L. (2025). CLDN22 Serves as a Novel Prognostic Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis.. International journal of genomics. https://doi.org/10.1155/ijog/9367254

Source records